Inozyme Pharma, Inc.

NASDAQ:INZY

1.41 (USD) • At close January 24, 2025
Bedrijfsnaam Inozyme Pharma, Inc.
Symbool INZY
Munteenheid USD
Prijs 1.41
Beurswaarde 90,578,682
Dividendpercentage 0%
52-weken bereik 1.235 - 7.795
Industrie Biotechnology
Sector Healthcare
CEO Dr. Douglas A. Treco Ph.D.
Website https://www.inozyme.com

Over Inozyme Pharma, Inc.

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for

Vergelijkbare Aandelen

OptiNose, Inc. logo

OptiNose, Inc.

OPTN

6.55 USD

Omeros Corporation logo

Omeros Corporation

OMER

8.37 USD

Longeveron Inc. logo

Longeveron Inc.

LGVN

1.68 USD

Biomea Fusion, Inc. logo

Biomea Fusion, Inc.

BMEA

4.41 USD

Co-Diagnostics, Inc. logo

Co-Diagnostics, Inc.

CODX

0.804 USD

Chimerix, Inc. logo

Chimerix, Inc.

CMRX

3.96 USD

Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc.

MIST

2.05 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)